Zepbound Injection, Solution
Product Images NDC 0002-3544

Product Visual Gallery

This gallery contains 98 technical images submitted to the FDA as part of the official labeling for Zepbound (NDC 0002-3544). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Zep Uspi Chem V1)

Chemical structure diagram of tirzepatide, the active ingredient in Zepbound, showing its peptide sequence and molecular connections.*

FDA Label Image

Figure 1 (Zep Uspi Fig1 V1)

A cumulative frequency plot depicting the percentage change in body weight on the x-axis versus cumulative frequency (%) on the y-axis. The graph includes curves for Zepbound injection solution at doses of 5 mg, 10 mg, and 15 mg, as well as a placebo group, illustrating the distribution of body weight change among subjects.*

FDA Label Image

Figure 2 (Zep Uspi Fig2 V1)

A cumulative frequency graph showing the percentage of subjects versus change in body weight (%). The plot compares three groups: Zepbound 10 mg, Zepbound 15 mg, and Placebo, illustrating body weight change distribution across these treatments.*

FDA Label Image

Figure 3 (Zep Uspi Fig3 V1)

A line graph depicting the percent change in body weight over 72 weeks post randomization for Zepbound injection at 5 mg, 10 mg, and 15 mg doses compared to placebo. The graph shows weight reduction trends, with the 10 mg and 15 mg doses showing the greatest decreases. Patient counts at various weeks for each group are listed below the graph.*

FDA Label Image

Figure 4 (Zep Uspi Fig4 V1)

A line graph depicting the percentage change in body weight over 72 weeks post-randomization for Zepbound 10 mg, Zepbound 15 mg, and placebo groups. The graph shows a greater decrease in body weight for both Zepbound doses compared to placebo, with numerical data on participant counts at various time points included below the graph.*

FDA Label Image

Figure 5 (Zep Uspi Fig5 V1)

A line graph depicting the percentage change in body weight over time in weeks relative to randomization for three groups: lead-in lifestyle, Zepbound MTD, and placebo. The Zepbound MTD group shows a marked weight decrease over 72 weeks, while the placebo and lead-in lifestyle groups show minimal change. Patient numbers for each group are listed below the x-axis at various weeks.*

FDA Label Image

Figure 6 (Zep Uspi Fig6 V1)

A line chart depicting the percentage change in body weight over 88 weeks for patients receiving Zepbound (tirzepatide) and placebo. The chart shows three groups: Zepbound Lead-in, Zepbound MTD, and Placebo, with weight change on the y-axis and weeks on the x-axis. Zepbound groups show significant weight reduction over time compared to placebo, which shows lesser weight loss.*

FDA Label Image

Figure 7 (Zep Uspi Fig7 V1)

A line graph comparing the change in AHI (apnea-hypopnea index) events per hour over 52 weeks post randomization between Zepbound MTD and placebo groups. The graph shows a significant decrease in AHI for the Zepbound group, from 0 to approximately -27.5 at week 52, while the placebo group shows minimal change around -4.3 events/hr. The number of patients at each time point is indicated below the x-axis.*

FDA Label Image

Figure (Zep Pen Ifu 1 V2)

Zepbound injection pen device shown for subcutaneous administration of tirzepatide. The pen includes a transparent barrel revealing internal components, a gray injection needle cover, a white midsection with a rectangular label area, and a white cap with green and purple markers on the right end. Manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Zep Pen Ifu 2 V1)

An instructional diagram of the Zepbound tirzepatide subcutaneous injection pen. The diagram labels the pen's components including the purple injection button at the top, lock ring, indicator, lock or unlock icon, medicine reservoir, clear base, gray base cap, and the bottom with needle end. The pen is oriented vertically with directional arrows for top and bottom.*

FDA Label Image

Figure (Zep Pen Ifu 3 V1)

An instructional illustration of a Zepbound injection pen highlighting the location of the expiration date on the device, indicated by a marked area on the pen's barrel near the bottom.*

FDA Label Image

Figure (Zep Pen Ifu 4a V1)

An instructional illustration showing recommended subcutaneous injection sites on the human body for Zepbound (tirzepatide) injection. The highlighted areas include the abdomen around the navel and the front thigh regions.*

FDA Label Image

Figure (Zep Pen Ifu 4b V1)

Illustration showing the recommended injection sites for Zepbound (tirzepatide) solution for subcutaneous injection. The image depicts a human figure highlighting the outer upper arm areas in purple as appropriate locations for injection.*

FDA Label Image

Figure (Zep Pen Ifu 5 V1)

An instructional illustration showing how to remove the gray base cap from the clear base of a Zepbound (tirzepatide) injection pen. It depicts a hand holding the pen and another hand pulling down the gray base cap away from the clear base, with a red arrow indicating the removal direction.*

FDA Label Image

Figure (Zep Pen Ifu 6 V1)

An instructional illustration showing a person administering a subcutaneous injection with a prefilled pen device into the abdomen. The image emphasizes the injection technique used for administering Zepbound (tirzepatide) injection solution.*

FDA Label Image

Figure (Zep Pen Ifu 7 V1)

An instructional illustration depicting a hand holding a Zepbound injection pen. It shows a red arrow indicating a twisting motion to unlock the pen before use, highlighting the unlocking mechanism with green unlock symbols.*

FDA Label Image

Figure (Zep Pen Ifu 8 V1)

An instructional illustration showing a person administering Zepbound injection solution subcutaneously into the abdomen using a prefilled injector device. The image depicts the hand holding the injector angled against the skin near the abdominal area.*

FDA Label Image

Figure (Zep Pen Ifu 9 V1)

An instructional diagram showing a close-up view of an injection pen with a labeled gray plunger component. The image highlights the gray plunger part of the device used for subcutaneous administration.*

FDA Label Image

Figure (Zep Pen Ifu 10 V1)

An illustration diagram showing a close-up of an injection device component labeled with an arrow pointing to the gray plunger. The image highlights the gray plunger within the injection syringe mechanism.*

FDA Label Image

Figure (Zep Qr)

FDA Label Image

Figure (Logo)

FDA Label Image

Figure (Zep Vial Ifu 1 V1)

An illustration of a vial labeled Zepbound (tirzepatide) injection. The vial features a protective cap and a rubber stopper beneath the cap, indicating components for subcutaneous injection.*

FDA Label Image

Figure (Zep Vial Ifu 2 V1)

An instructional diagram of a syringe labeled with parts including Needle Shield, Needle, Plunger Tip, Plunger, and Syringe Body. A magnified section highlights the measurement markings on the syringe between 0.4 mL and 0.6 mL, with a prominent dose mark at 0.5 mL.*

FDA Label Image

Figure (Zep Vial Ifu 3 V1)

An instructional illustration showing hands holding a vial of Zepbound (tirzepatide) injection solution. One hand grips the vial, while the other hand is pulling off the vial cap, indicated by an upward arrow. The image demonstrates how to open the vial prior to subcutaneous injection.*

FDA Label Image

Figure (Zep Vial Ifu 4 V1)

Illustration depicting a pair of hands removing a cap from a small vial or injection bottle, likely demonstrating preparation steps for a subcutaneous injection, consistent with the Zepbound (tirzepatide) injection product.*

FDA Label Image

Figure (Zep Vial Ifu 5 V1)

An instructional illustration showing how to prepare a medication by injecting or drawing liquid from a cylindrical vial or container using a syringe, held and manipulated with both hands.*

FDA Label Image

Figure (Zep Vial Ifu 6 V1)

An instructional line drawing showing hands peeling off a protective cap or cover from a small object, likely indicating a step in the preparation or use of a medication injection device such as Zepbound (tirzepatide) injection.*

FDA Label Image

Figure (Zep Vial Ifu 7 V1)

An illustration showing a ribbon being removed from a capped injector pen device, likely demonstrating part of the preparation or use instructions for Zepbound injection solution by Eli Lilly and Company.*

FDA Label Image

Figure (Zep Vial Ifu 8 V1)

An instructional illustration showing hands holding a syringe with an arrow pointing left, indicating the removal direction of the syringe cap or protective cover prior to injection.*

FDA Label Image

Figure (Zep Vial Ifu 9 V1)

An instructional diagram showing a hand holding and preparing a syringe for injection. The image emphasizes pushing the syringe plunger downward to expel air bubbles, with a close-up view of the syringe barrel containing a small amount of liquid at the 0.05 mL mark.*

FDA Label Image

Figure (Zep Vial Ifu 10 V1)

An instructional illustration showing a person drawing a solution from a vial into a syringe. The image focuses on proper syringe usage, depicting the vial held in one hand and the syringe being inserted into the vial with an arrow indicating the motion.*

FDA Label Image

Figure (Zep Vial Ifu 11 V1)

Illustration showing the correct technique for drawing medication from a vial into a syringe. One hand holds the vial upside down while the other hand pulls back the plunger of the syringe to draw the liquid. An arrow indicates the direction to pull the plunger.*

FDA Label Image

Figure (Zep Vial Ifu 12 V1)

An instructional illustration showing a hand holding a syringe with a needle pointing upwards and a close-up view of the syringe's measurement markings from 0.0 to 0.5 mL. This diagram is likely demonstrating how to properly measure or prepare an injection dose for a subcutaneous injection.*

FDA Label Image

Figure (Zep Vial Ifu 13 V1)

An instructional illustration showing two hands preparing a syringe for injection. One hand holds an inverted vial while the other hand pulls the syringe plunger to draw medication from the vial, depicting a typical step in preparing a subcutaneous injection.*

FDA Label Image

Figure (Zep Vial Ifu 14 V1)

An instructional illustration showing hands drawing medication from a vial into a syringe, with an inset close-up of the syringe barrel marked with volume measurements from 0.1 to 0.5 mL. The image includes an upward arrow indicating the direction for pulling back the plunger.*

FDA Label Image

Figure (Zep Vial Ifu 15 V1)

An instructional illustration showing a hand holding a vial with its cap being removed and another hand holding a syringe pointed upwards, indicating the step of drawing medication from the vial into the syringe.*

FDA Label Image

Figure (Zep Vial Ifu 16 V1)

Illustration showing the recommended subcutaneous injection sites on the human body for Zepbound (tirzepatide) injection solution. It highlights the abdomen and the front thigh areas as appropriate injection locations.*

FDA Label Image

Figure (Zep Vial Ifu 17 V1)

An anatomical illustration showing the back view of a human body with shaded areas on both upper arms, indicating possible sites for subcutaneous injection administration.*

FDA Label Image

Figure (Zep Vial Ifu 18 V1)

An instructional line drawing showing a person administering a subcutaneous injection into the lower abdomen. The individual uses one hand to pinch the skin and holds a syringe in the other, ready to inject. The image includes an arrow indicating the injection site area on the abdomen above the waistline.*

FDA Label Image

Figure (Zep Vial Ifu 19 V1)

An instructional illustration showing a person administering a subcutaneous injection in the abdomen area. The image depicts the hand holding a syringe and the injection site just above the waistband.*

FDA Label Image

Figure (Zep Vial Ifu 20 V1)

Black and white instructional illustration showing a hand holding a syringe to administer a subcutaneous injection in the neck area of a person's skin, with an arrow indicating the direction of injection.*

FDA Label Image

Figure (Zep Vial Mdv Ifu 2 V1)

An illustration diagram of a syringe for subcutaneous injection. It labels the parts: needle shield, needle, plunger tip, syringe body with volume markings up to 1 mL, and plunger. A magnified inset shows the syringe volume markings between 0.5 and 0.7 mL highlighted.*

FDA Label Image

Figure (Zep Vial Mdv Ifu 9 V1)

An instructional illustration showing a hand holding a syringe with the needle inserted into a vial or rubber stopper. An arrow indicates a downward motion, suggesting pushing the plunger to draw or expel fluid. A close-up shows the syringe's dosage markings from 0.1 to 0.6 mL for accurate measurement.*

FDA Label Image

Figure (Zep Vial Mdv Ifu 14 V1)

An instructional diagram showing two hands preparing an injection. One hand holds a vial upside down while the other pulls back the plunger of a syringe to draw liquid. The syringe is marked in increments from 0.1 to 0.6 mL, with the liquid level near 0.6 mL. An upward arrow indicates the motion of drawing fluid from the vial into the syringe.*

FDA Label Image

Figure (Zep Kp 1 Pen V1)

Zepbound subcutaneous injection pen device for tirzepatide delivery, featuring a white and gray body with a purple cap and a numeric dose indicator window, consistent with a prescription drug injection system by Eli Lilly and Company.*

FDA Label Image

Figure (Zep Kp 2 Pen Parts V2)

Illustration diagram of Zepbound (tirzepatide) injection pen parts and pen needle components. The labeled pen parts include pen cap with cap clip, cartridge and plunger, cartridge holder, pen body with label, dose indicator within the dose window, and dose knob. Pen needle parts shown separately include outer needle shield, inner needle shield, needle, and paper tab, with a note that needles are not included. The diagram highlights a red inner seal detail on the cartridge tip.*

FDA Label Image

Figure (Zep Kp 17 Dial 1 Zoom V1)

FDA Label Image

Figure (Zep Kp 3 Wash V1)

An instructional illustration showing two hands with soap bubbles, demonstrating the handwashing process. The image emphasizes proper hygiene practices, likely related to the preparation or handling of the drug product Zepbound (tirzepatide) injection.*

FDA Label Image

Figure (Zep Kp 4 Uncap V1)

An instructional illustration showing a close-up of a syringe with a protective cap being removed by pulling it in the direction indicated by a left-pointing red arrow. The image is likely part of usage instructions for the Zepbound (tirzepatide) injection solution syringe.*

FDA Label Image

Figure (Zep Kp 5 Wipe V1)

This illustration shows hands removing a protective cap from the tip of a syringe or injection pen, with an arrow indicating the direction to pull the cap off. It demonstrates a preparatory step for subcutaneous injection.*

FDA Label Image

Figure (Zep Kp 6 New Needle Tab V1)

An instructional illustration showing a hand lifting the cap off a small vial or injection pen with a red arrow indicating the upward motion for removing the cap before use.*

FDA Label Image

Figure (Zep Kp 7 Attach Needle V1)

An instructional illustration showing a step in using an injection device for Zepbound (tirzepatide). It depicts a close-up of the device's dial with arrows indicating a twisting motion, likely for dose setting or preparation before injection.*

FDA Label Image

Figure (Zep Kp 8 Outer Shield V1)

An instructional illustration showing the removal of a protective cap from an injection pen. The image includes an upward-pointing red arrow indicating the direction to pull the cap off the pen tip, relevant to the preparation of Zepbound (tirzepatide) injection for subcutaneous use.*

FDA Label Image

Figure (Zep Kp 9 Inner Shield V1)

An instructional illustration showing the removal of a protective cap from a syringe needle. The image depicts the syringe with the cap above it and an upward arrow indicating to pull the cap straight off prior to use.*

FDA Label Image

Figure (Zep Kp 10 Dial Clicks V1)

Instructional illustration showing a hand peeling back a protective seal or label from a rectangular surface, likely part of an injection device or packaging for Zepbound (tirzepatide) injection, solution, subcutaneous.*

FDA Label Image

Figure (Zep Kp 11 Dial Zoom V1)

Zepbound 15 mg/0.5 mL injection, solution in a prefilled syringe carton. The packaging shows the proprietary name Zepbound, active ingredient tirzepatide, and strength of 15 mg per 0.5 mL. The product is for subcutaneous use and is labeled by Eli Lilly and Company. The box indicates the package contains 4 prefilled syringes.*

FDA Label Image

Figure (Zep Kp 12 Tap V1)

Illustration showing a hand holding a syringe injection pen with the other hand positioned to push the plunger. An arrow points upward from the syringe needle, indicating an injection or dosing action, likely demonstrating how to use the injection device for subcutaneous administration.*

FDA Label Image

Figure (Zep Kp 13 5sec Hold V1)

An instructional illustration showing a hand holding a prefilled injection pen with an arrow pointing upward to indicate removing the cap. A close-up inset highlights the needle tip. A stopwatch icon with text instructs to hold the injection pen in place for 5 seconds after insertion. This diagram relates to the proper use of the Zepbound (tirzepatide) injection pen for subcutaneous administration.*

FDA Label Image

Figure (Zep Kp 14 Zero Dial Zoom V1)

Zepbound 10 mg/0.5 mL injection solution in a prefilled pen syringe, for subcutaneous use. The label shows the product name, active ingredient tirzepatide, strength, and administration form. The labeler is Eli Lilly and Company. The pen contains 0.5 mL of the medication and has a purple cap.*

FDA Label Image

Figure (Zep Kp 15 Inj Sites V1)

An instructional diagram showing recommended subcutaneous injection sites on a human body. Marked areas for injection include the abdomen around the navel, front and outer sides of the thighs, and the back of the upper arms.*

FDA Label Image

Figure (Zep Kp 16 Dial 1 Dose V1)

An instructional illustration showing a hand dialing the dose setting on a pen injector device for a medication, demonstrating how to adjust the dosage before injection.*

FDA Label Image

Figure (Zep Kp 18 Insert Needle V1)

An instructional illustration showing a hand holding a prefilled injection pen, aimed at the abdomen with an arrow indicating the direction of the injection for subcutaneous administration.*

FDA Label Image

Figure (Zep Kp 19 Push Hold V1)

An instructional diagram showing how to use a subcutaneous injection pen. It illustrates pressing the injection button firmly for 5 seconds to ensure full delivery, indicated by a red 'PUSH' arrow and a stopwatch icon with '5 sec. HOLD' instructions.*

FDA Label Image

Figure (Zep Kp 20 Remove V1)

An instructional illustration showing a hand holding a prefilled injection device near the abdomen, indicating subcutaneous injection. A red arrow points leftward, suggesting the direction or motion for the injection process.*

FDA Label Image

Figure (Zep Kp 21 Cotton Ball V1)

Instructional illustration showing a person administering a subcutaneous injection, with the needle inserted into the skin and an arrow indicating the direction of injection. The image likely relates to the administration of Zepbound (tirzepatide) injection.*

FDA Label Image

Figure (Zep Kp 22 Recap Shield V1)

An instructional illustration showing a hand grasping an injection pen, removing the protective cap by pulling it away from the needle. The diagram indicates the step for preparing the tirzepatide injection device for subcutaneous administration.*

FDA Label Image

Figure (Zep Kp 23 Remove Needle V1)

Illustration showing a hand removing the cap from an injection pen or device. A strip of red adhesive or packaging tape is partially peeled back from the device, indicating preparation steps for use.*

FDA Label Image

Figure (Zep Kp 24 Recap Pen V1)

An instructional diagram showing a prefilled injection pen with its cap partially removed, accompanied by a red arrow indicating the direction to pull the cap off. This illustrates how to remove the cap from the Zepbound injection pen before use.*

FDA Label Image

Package Label (Zepbound Prefilled Pen (Autoinjector))

Packaging label for Zepbound (tirzepatide) injection, 2.5 mg/0.5 mL, a subcutaneous injection. The label shows the brand and generic names, dosage strength, and indicates the package contains 4 single-dose prefilled pens. It includes usage directions stating to use one pen weekly. The manufacturer is Eli Lilly and Company.*

FDA Label Image

Package Label (Zepbound Prefilled Pen (Autoinjector))

Zepbound 5 mg/0.5 mL (tirzepatide) injection packaging label showing a box containing 4 single-dose prefilled pens for subcutaneous use. The label includes the product name, strength, dosage form, quantity of prefilled pens, and manufacturer Eli Lilly and Company. The design features green and purple accents with an image of a prefilled pen.*

FDA Label Image

Package Label (Zepbound Prefilled Pen (Autoinjector))

Zepbound 7.5 mg/0.5 mL (tirzepatide) injection carton by Eli Lilly and Company. The package contains 4 single-dose prefilled pens for subcutaneous injection. The front of the carton shows the product name, strength, dosage form, quantity, and usage instructions, along with an image of a prefilled pen. The design uses green and white colors with pink side flaps.*

FDA Label Image

Package Label (Zepbound Prefilled Pen (Autoinjector))

Packaging label for Zepbound 10 mg/0.5 mL injection, containing 4 single-dose prefilled pens for subcutaneous use. The label shows the proprietary name Zepbound, the generic name tirzepatide injection, strength, and the manufacturer Eli Lilly and Company. It includes usage instructions such as using one pen every week and dispensing an enclosed medication guide.*

FDA Label Image

Package Label (Zepbound Prefilled Pen (Autoinjector))

Packaging label for Zepbound (tirzepatide) injection 12.5 mg/0.5 mL by Eli Lilly and Company. The carton contains 4 single-dose prefilled pens for subcutaneous injection. The front shows product name, strength, dosage form, and a pen image. Usage instructions note one pen per week and Rx-only status.*

FDA Label Image

Package Label (Zepbound Prefilled Pen (Autoinjector))

Packaging label for Zepbound (tirzepatide) injection 15 mg/0.5 mL by Eli Lilly and Company. The label indicates the product is a single-dose, subcutaneous injection available as prefilled pens. The carton contains 4 prefilled pens with 15 mg/0.5 mL dosage strength, with instructions for use once weekly.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Zepbound (tirzepatide) injection 2.5 mg/0.5 mL carton label shows the product name and strength, specifying it as a subcutaneous injection. The label indicates a prescription-only status, storage instructions to refrigerate between 2°C to 8°C, and mentions that needles and syringes are not included. The labeler is Eli Lilly and Company, Indianapolis, IN, USA. The packaging contains 4 single-dose vials with directions for use and disposal.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection, 2.5 mg/0.5 mL, a subcutaneous injection. The label indicates it contains 4 single-dose vials. It is labeled for prescription use only and is marketed by Eli Lilly and Company. Storage instructions specify refrigeration at 2°C to 8°C and to keep out of reach of children. Additional details include no preservative and the need to dispense an enclosed Medication Guide.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Box label for Zepbound 5 mg/0.5 mL injection, containing tirzepatide. The label indicates it is for subcutaneous use, marked by Eli Lilly and Company. The packaging states the product contains 4 single-dose vials and includes storage instructions, noting refrigeration and room temperature conditions.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection, 5 mg/0.5 mL, marketed by Eli Lilly and Company. The label indicates it is for subcutaneous use, Rx only, with 4 single-dose vials per carton. Storage instructions note refrigeration at 2 to 8°C and to avoid freezing. The label includes barcodes, dosing guidance references, and a medication guide mention.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound 7.5 mg/0.5 mL tirzepatide injection solution. The label indicates it is for subcutaneous use, Rx only, marketed by Eli Lilly and Company. The carton contains 4 single-dose vials and includes storage instructions to refrigerate at 2°C to 8°C and not to freeze. The label highlights no preservatives and standard potency.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection 7.5 mg/0.5 mL, a subcutaneous injection by Eli Lilly and Company. The carton contains 4 single-dose vials. The label includes storage instructions, dosage recommendations, and a barcode. It notes this is a prescription drug without preservatives and with no U.S. standard of potency.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Carton label for Zepbound (tirzepatide) injection, 10 mg/0.5 mL, for subcutaneous use. The label states it is Rx only, marketed by Eli Lilly and Company, and includes instructions for storage from 2°C to 8°C, with use guidelines. The package contains 4 single-dose vials. The design features the Zepbound logo in green and purple alongside dosing and usage information.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection 10 mg/0.5 mL by Eli Lilly and Company. The label indicates 4 single-dose vials for subcutaneous use with instructions to use one vial weekly. Storage instructions specify refrigeration at 2°C to 8°C, no freezing, and storage out of light. The label includes a barcode and manufacturer details from Lilly USA, LLC, Indianapolis.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Label for Zepbound tirzepatide injection 12.5 mg/0.5 mL by Eli Lilly and Company. The label indicates a single-dose vial for subcutaneous use, with storage instructions to refrigerate between 2°C to 8°C and to not freeze. The package includes 4 single-dose vials and instructs users to dispense an enclosed medication guide with each patient. The label also states no preservatives or syringes are included and provides storage and disposal recommendations.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection, 12.5 mg/0.5 mL. The label indicates subcutaneous use with a package containing 4 single-dose vials. Marketed by Lilly USA, LLC, the label includes storage instructions, dosage recommendations, and regulatory details. The label design features the Zepbound logo in green and blue on a white background with pink accents.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Zepbound 15 mg/0.5 mL injection solution label for subcutaneous use by Eli Lilly and Company. The label shows the proprietary name, generic name tirzepatide, dosage strength, NDC numbers, and instructions indicating Rx only, storage conditions, and disposal of single-dose vials. The packaging includes a barcode and company contact information.*

FDA Label Image

Package Label (Zepbound Single-Dose Vial)

Packaging label for Zepbound tirzepatide injection 15 mg/0.5 mL in a set of 4 single-dose vials. The label indicates the product is a subcutaneous injection for prescription use, marketed by Lilly USA, LLC. Storage instructions specify refrigeration at 2°C to 8°C with no freezing. The label includes dosage, storage, and manufacturer details along with a barcode.*

FDA Label Image

Package Label (Zepbound Multi-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection 10 mg/2.4 mL (4.17 mg/mL) by Eli Lilly and Company. The multi-dose vial contains 4 doses of 2.5 mg/0.6 mL in a 2.4 mL vial for subcutaneous use. It includes storage instructions, a barcode, and warnings that needles and syringes are not included and to dispense the Medication Guide to each patient.*

FDA Label Image

Package Label (Zepbound Multi-Dose Vial)

Label for Zepbound (tirzepatide) injection 20 mg/2.4 mL (8.33 mg/mL) by Eli Lilly and Company. The multi-dose vial contains 4 doses of 5 mg/0.6 mL each and is for subcutaneous use. The label includes storage instructions, dosage warnings, and a note that needles and syringes are not included. The package instructs to dispense an enclosed medication guide to each patient.*

FDA Label Image

Package Label (Zepbound Multi-Dose Vial)

Zepbound (tirzepatide) injection 30 mg/2.4 mL (12.5 mg/mL) vial label by Eli Lilly and Company. The label indicates a 2.4 mL multi-dose vial containing 4 doses of 7.5 mg/0.6 mL, for subcutaneous use. It includes storage instructions, inactive ingredients, and a notice to dispense the enclosed medication guide. The label shows the NDC 0002-6210-11 and barcode.*

FDA Label Image

Package Label (Zepbound Multi-Dose Vial)

Packaging label for Zepbound (tirzepatide) injection 40 mg/2.4 mL (16.7 mg/mL) multi-dose vial. The label includes dosage instructions, storage conditions, and warnings about vial usage. It states subcutaneous route and that needles and syringes are not included. Labeler is Eli Lilly and Company. The design includes green and magenta text blocks with safety and usage information.*

FDA Label Image

Package Label (Zepbound Multi-Dose Vial)

Zepbound (tirzepatide) injection carton label for 50 mg/2.4 mL (20.8 mg/mL) subcutaneous solution by Eli Lilly and Company. The label states it contains 4 doses of 12.5 mg/0.6 mL in a 2.4 mL multi-dose vial, with instructions to store refrigerated or at room temperature and warnings about discarding unused portions 30 days after first use. It notes that needles and syringes are not included and that a medication guide is provided.*

FDA Label Image

Package Label (Zepbound Multi-Dose Vial)

Zepbound (tirzepatide) injection 60 mg/2.4 mL (25 mg/mL) multi-dose vial label by Eli Lilly and Company. The label includes dosage form as subcutaneous injection, storage instructions, and warnings that the vial contains 4 doses of 15 mg/0.6 mL and should be discarded 30 days after first use. It also advises that needles and syringes are not included and a medication guide should be dispensed to each patient.*

FDA Label Image

Package Label – Zepbound Kwikpen – 2.5 mg Per Dose (10 mg/2.4 mL [4.17 mg/ml]) (Zep Carton 2pt5mg Kp 031 00)

Packaging label for Zepbound KwikPen (tirzepatide) injection, solution 2.5 mg per dose, with a total volume of 10 mg/2.4 mL at 4.17 mg/mL concentration. The carton contains 1 single-patient-use KwikPen delivering 4 doses of 2.5 mg each. The label includes dosing instructions, storage conditions, and notes that needles are not included. Manufactured and marketed by Eli Lilly and Company.*

FDA Label Image

Package Label – Zepbound Kwikpen – 5 mg Per Dose (20 mg/2.4 mL [8.33 mg/ml]) (Zep Carton 5mg Kp 030 00)

Packaging label for Zepbound KwikPen injection, containing tirzepatide at a strength of 5 mg per dose in a 20 mg/2.4 mL (8.33 mg/mL) solution. The label indicates a single-prepared pen with 4 doses of 5 mg each, for subcutaneous use. It includes storage instructions, contents of the carton, and manufacturer details as Eli Lilly and Company.*

FDA Label Image

Package Label – Zepbound Kwikpen – 7.5 mg Per Dose (30 mg/2.4 mL [12.5 mg/ml]) (Zep Carton 7pt5mg Kp 029 00)

Zepbound KwikPen 7.5 mg per dose (tirzepatide) injection solution in a prefilled single-patient-use pen delivering 4 doses of 7.5 mg each. The package contains 30 mg/2.4 mL (12.5 mg/mL) and is labeled for subcutaneous use. The label includes dosing instructions, storage guidelines, and notes that needles are not included. Manufactured by Eli Lilly and Company.*

FDA Label Image

Package Label – Zepbound Kwikpen – 10 mg Per Dose (40 mg/2.4 mL [16.7 mg/ml]) (Zep Carton 10mg Kp 028 00)

Packaging label for Zepbound KwikPen (tirzepatide) injection, 10 mg per dose, 40 mg/2.4 mL (16.7 mg/mL) dosage form. This single-patient-use pen contains 4 doses of 10 mg each for subcutaneous injection. Label shows dosing knob instruction and storage guidelines. Marketed by Eli Lilly and Company. Includes usage warnings, storage conditions, and details on carton contents.*

FDA Label Image

Package Label – Zepbound Kwikpen – 12.5 mg Per Dose (50 mg/2.4 mL [20.8 mg/ml]) (Zep Carton 12pt5mg Kp 027 00)

Packaging label for Zepbound KwikPen 12.5 mg per dose (tirzepatide) injection by Eli Lilly and Company. The label indicates a single-patient-use prefilled injection pen containing 4 doses of 12.5 mg each, with a concentration of 50 mg/2.4 mL (20.8 mg/mL). Instructions include storing unused pens refrigerated, discarding the pen 30 days after use, and notes that needles are not included. The label also features dosing instructions with a dose knob and regulatory information.*

FDA Label Image

Package Label – Zepbound Kwikpen – 15 mg Per Dose (60 mg/2.4 mL [25 mg/ml]) (Zep Carton 15mg Kp 026 00)

Zepbound KwikPen 15 mg per dose (tirzepatide) injection in a 2.4 mL prefilled pen containing 4 doses of 15 mg each. The label instructs subcutaneous use, once weekly dosing, and notes needles are not included. Storage guidelines, discard instructions, inactive ingredients, and manufacturer Eli Lilly and Company details are provided. The packaging includes usage instructions and warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.